Analyst Price Targets — CELC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 26, 2026 2:49 pm | — | Craig-Hallum | $141.00 | $114.81 | TheFly | Celcuity price target raised to $141 from $108 at Craig-Hallum |
| March 12, 2026 1:58 pm | Kalpit Patel | Wolfe Research | $110.00 | $110.73 | StreetInsider | Wolfe Research Reiterates Outperform Rating on Celcuity Inc (CELC): "Relay's update does not appear to change the efficacy benchmark" |
| March 10, 2026 11:08 am | Gil Blum | Needham | $122.00 | $115.94 | StreetInsider | Celcuity Inc (CELC) PT Raised to $122 at Needham |
| December 12, 2025 11:38 am | — | Wells Fargo | $126.00 | $100.70 | TheFly | Celcuity initiated with an Overweight at Wells Fargo |
| October 22, 2025 10:05 am | Swayampakula Ramakanth | H.C. Wainwright | $77.00 | $65.22 | TheFly | Celcuity price target raised to $77 from $66 at H.C. Wainwright |
| October 20, 2025 3:14 pm | — | Needham | $95.00 | $72.14 | TheFly | Celcuity price target raised to $95 from $70 at Needham |
| August 15, 2024 8:09 am | Bradley Canino | Stifel Nicolaus | $39.00 | $16.57 | StreetInsider | Celcuity Inc (CELC) PT Lowered to $39 at Stifel |
| May 30, 2024 2:29 pm | Bradley Canino | Stifel Nicolaus | $40.00 | $15.28 | StreetInsider | Stifel Reiterates Buy Rating on Celcuity Inc (CELC) |
| March 28, 2024 7:08 am | Gil Blum | Needham | $24.00 | $18.16 | StreetInsider | Celcuity Inc (CELC) PT Raised to $24 at Needham |
Latest News for CELC
Nisa Investment Advisors LLC lowered its stake in shares of Celcuity, Inc. (NASDAQ: CELC) by 96.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 508 shares of the company's stock after selling 15,119 shares during the period. Nisa
It very much surprised on the upside on the bottom-line result. It also has a much longer cash runway than it did at the end of 2024.
Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript
MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2025, and other recent business developments.
MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2025 after the market closes on Wednesday, March 25, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CELC.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.